...
search icon
abus-img

Arbutus Biopharma Corp, Common Stock

ABUS

NSQ

$3.34

+$0.05

(1.52%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$614.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
625.36K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.45
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.63 L
$4.72 H
$3.34

About Arbutus Biopharma Corp, Common Stock

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameABUSSectorS&P500
1-Week Return4.05%4.13%7.14%
1-Month Return-4.57%-4.48%-0.92%
3-Month Return-0.3%-5.78%-8.95%
6-Month Return-17.53%-7.23%-5.21%
1-Year Return20.14%-1.69%7.95%
3-Year Return37.45%3.23%28.74%
5-Year Return178.33%38.7%92.67%
10-Year Return-79.89%88.08%161.14%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue6.91M10.99M39.02M18.14M6.17M[{"date":"2020-12-31","value":17.72,"profit":true},{"date":"2021-12-31","value":28.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.49,"profit":true},{"date":"2024-12-31","value":15.82,"profit":true}]
Cost of Revenue47.48M1.75M1.43M73.70M-[{"date":"2020-12-31","value":64.42,"profit":true},{"date":"2021-12-31","value":2.38,"profit":true},{"date":"2022-12-31","value":1.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(40.57M)9.23M37.59M(55.56M)6.17M[{"date":"2020-12-31","value":-107.91,"profit":false},{"date":"2021-12-31","value":24.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-147.79,"profit":false},{"date":"2024-12-31","value":16.42,"profit":true}]
Gross Margin(586.74%)84.05%96.34%(306.26%)100.00%[{"date":"2020-12-31","value":-586.74,"profit":false},{"date":"2021-12-31","value":84.05,"profit":true},{"date":"2022-12-31","value":96.34,"profit":true},{"date":"2023-12-31","value":-306.26,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses64.18M82.64M102.24M96.24M82.49M[{"date":"2020-12-31","value":62.78,"profit":true},{"date":"2021-12-31","value":80.83,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.13,"profit":true},{"date":"2024-12-31","value":80.68,"profit":true}]
Operating Income(57.81M)(73.52M)(65.46M)(78.10M)(76.32M)[{"date":"2020-12-31","value":-5780600000,"profit":false},{"date":"2021-12-31","value":-7352200000,"profit":false},{"date":"2022-12-31","value":-6545600000,"profit":false},{"date":"2023-12-31","value":-7810300000,"profit":false},{"date":"2024-12-31","value":-7631900000,"profit":false}]
Total Non-Operating Income/Expense(9.21M)(5.46M)910.00K9.70M12.85M[{"date":"2020-12-31","value":-71.68,"profit":false},{"date":"2021-12-31","value":-42.46,"profit":false},{"date":"2022-12-31","value":7.08,"profit":true},{"date":"2023-12-31","value":75.47,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(63.74M)(76.25M)(65.01M)(72.85M)(69.92M)[{"date":"2020-12-31","value":-6374500000,"profit":false},{"date":"2021-12-31","value":-7624700000,"profit":false},{"date":"2022-12-31","value":-6501200000,"profit":false},{"date":"2023-12-31","value":-7284900000,"profit":false},{"date":"2024-12-31","value":-6992000000,"profit":false}]
Income Taxes1.47M1.10M4.44M(1.00)-[{"date":"2020-12-31","value":32.99,"profit":true},{"date":"2021-12-31","value":24.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(65.21M)(77.35M)(69.46M)(72.85M)-[{"date":"2020-12-31","value":-6521100000,"profit":false},{"date":"2021-12-31","value":-7735100000,"profit":false},{"date":"2022-12-31","value":-6945600000,"profit":false},{"date":"2023-12-31","value":-7284899900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(63.74M)(76.25M)(69.46M)(75.47M)(69.92M)[{"date":"2020-12-31","value":-6374500000,"profit":false},{"date":"2021-12-31","value":-7624700000,"profit":false},{"date":"2022-12-31","value":-6945600000,"profit":false},{"date":"2023-12-31","value":-7546900000,"profit":false},{"date":"2024-12-31","value":-6992000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(65.21M)(77.35M)(69.46M)(72.85M)(69.92M)[{"date":"2020-12-31","value":-6521100000,"profit":false},{"date":"2021-12-31","value":-7735100000,"profit":false},{"date":"2022-12-31","value":-6945600000,"profit":false},{"date":"2023-12-31","value":-7284900000,"profit":false},{"date":"2024-12-31","value":-6992000000,"profit":false}]
EPS (Diluted)(1.00)(0.83)(0.47)(0.44)(0.40)[{"date":"2020-12-31","value":-100,"profit":false},{"date":"2021-12-31","value":-83,"profit":false},{"date":"2022-12-31","value":-47,"profit":false},{"date":"2023-12-31","value":-44,"profit":false},{"date":"2024-12-31","value":-39.99,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ABUS
Cash Ratio 7.85
Current Ratio 8.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABUS
ROA (LTM) -33.36%
ROE (LTM) -68.76%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABUS
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABUS
Trailing PE NM
Forward PE NM
P/S (TTM) 103.64
P/B 6.47
Price/FCF NM
EV/R 82.42
EV/Ebitda NM
PEG NM

FAQs

What is Arbutus Biopharma Corp share price today?

Arbutus Biopharma Corp (ABUS) share price today is $3.34

Can Indians buy Arbutus Biopharma Corp shares?

Yes, Indians can buy shares of Arbutus Biopharma Corp (ABUS) on Vested. To buy Arbutus Biopharma Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABUS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arbutus Biopharma Corp be purchased?

Yes, you can purchase fractional shares of Arbutus Biopharma Corp (ABUS) via the Vested app. You can start investing in Arbutus Biopharma Corp (ABUS) with a minimum investment of $1.

How to invest in Arbutus Biopharma Corp shares from India?

You can invest in shares of Arbutus Biopharma Corp (ABUS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABUS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arbutus Biopharma Corp shares
What is Arbutus Biopharma Corp 52-week high and low stock price?

The 52-week high price of Arbutus Biopharma Corp (ABUS) is $4.72. The 52-week low price of Arbutus Biopharma Corp (ABUS) is $2.63.

What is Arbutus Biopharma Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arbutus Biopharma Corp (ABUS) is 6.47

What is the Market Cap of Arbutus Biopharma Corp?

The market capitalization of Arbutus Biopharma Corp (ABUS) is $614.65M

What is Arbutus Biopharma Corp’s stock symbol?

The stock symbol (or ticker) of Arbutus Biopharma Corp is ABUS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top